FY2025 EPS Estimates for Pfizer Inc. Boosted by Analyst (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Zacks Research upped their FY2025 EPS estimates for Pfizer in a report issued on Wednesday, April 10th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings of $2.63 per share for the year, up from their previous forecast of $2.60. The consensus estimate for Pfizer's current full-year earnings is $2.22 per share. Zacks Research also issued estimates for Pfizer's Q4 2025 earnings at $0.74 EPS and FY2026 earnings at $2.64 EPS.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the business earned $1.14 EPS. The company's revenue for the quarter was down 41.3% on a year-over-year basis.

Several other brokerages also recently commented on PFE. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. UBS Group dropped their price target on shares of Pfizer from $34.00 to $27.00 and set a "neutral" rating on the stock in a report on Thursday, December 14th. Barclays dropped their price target on shares of Pfizer from $34.00 to $28.00 and set an "equal weight" rating on the stock in a report on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Finally, Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target on the stock. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $36.88.

Pfizer Stock Up 0.1 %

PFE stock traded up $0.02 during trading on Thursday, hitting $26.34. 32,800,341 shares of the stock traded hands, compared to its average volume of 42,843,055. Pfizer has a 1 year low of $25.61 and a 1 year high of $41.79. The firm's 50 day moving average is $27.32 and its two-hundred day moving average is $29.00. The stock has a market cap of $149.12 billion, a price-to-earnings ratio of 72.78, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Worth Asset Management LLC bought a new stake in Pfizer during the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the third quarter valued at approximately $30,000. Main Street Group LTD bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $30,000. GoalVest Advisory LLC raised its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 811 shares during the last quarter. Finally, Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $32,000. Institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.